drug
as of 2026-07-01NBI-1117568
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Neurocrine Biosciences
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
5
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874Phase 3Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Phase 3Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098Phase 3Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034Phase 3Recruiting
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111Phase 2Completed
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here